Cargando…
PROMISCUOUS 2.0: a resource for drug-repositioning
The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779026/ https://www.ncbi.nlm.nih.gov/pubmed/33196798 http://dx.doi.org/10.1093/nar/gkaa1061 |
_version_ | 1783631247763832832 |
---|---|
author | Gallo, Kathleen Goede, Andrean Eckert, Andreas Moahamed, Barbara Preissner, Robert Gohlke, Björn-Oliver |
author_facet | Gallo, Kathleen Goede, Andrean Eckert, Andreas Moahamed, Barbara Preissner, Robert Gohlke, Björn-Oliver |
author_sort | Gallo, Kathleen |
collection | PubMed |
description | The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-19 pandemic, drug repositioning has gained widespread attention as a fast opportunity to find potential treatments against the newly emerging disease. In order to expand this field to researchers with varying levels of experience, we made an effort to open it to all users (meaning novices as well as experts in cheminformatics) by significantly improving the entry-level user experience. The browsing functionality can be used as a global entry point to collect further information with regards to small molecules (∼1 million), side-effects (∼110 000) or drug-target interactions (∼3 million). The drug-repositioning tab for small molecules will also suggest possible drug-repositioning opportunities to the user by using structural similarity measurements for small molecules using two different approaches. Additionally, using information from the Promiscuous 2.0 Database, lists of candidate drugs for given indications were precomputed, including a section dedicated to potential treatments for COVID-19. All the information is interconnected by a dynamic network-based visualization to identify new indications for available compounds. Promiscuous 2.0 is unique in its functionality and is publicly available at http://bioinformatics.charite.de/promiscuous2. |
format | Online Article Text |
id | pubmed-7779026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77790262021-01-07 PROMISCUOUS 2.0: a resource for drug-repositioning Gallo, Kathleen Goede, Andrean Eckert, Andreas Moahamed, Barbara Preissner, Robert Gohlke, Björn-Oliver Nucleic Acids Res Database Issue The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-19 pandemic, drug repositioning has gained widespread attention as a fast opportunity to find potential treatments against the newly emerging disease. In order to expand this field to researchers with varying levels of experience, we made an effort to open it to all users (meaning novices as well as experts in cheminformatics) by significantly improving the entry-level user experience. The browsing functionality can be used as a global entry point to collect further information with regards to small molecules (∼1 million), side-effects (∼110 000) or drug-target interactions (∼3 million). The drug-repositioning tab for small molecules will also suggest possible drug-repositioning opportunities to the user by using structural similarity measurements for small molecules using two different approaches. Additionally, using information from the Promiscuous 2.0 Database, lists of candidate drugs for given indications were precomputed, including a section dedicated to potential treatments for COVID-19. All the information is interconnected by a dynamic network-based visualization to identify new indications for available compounds. Promiscuous 2.0 is unique in its functionality and is publicly available at http://bioinformatics.charite.de/promiscuous2. Oxford University Press 2020-11-16 /pmc/articles/PMC7779026/ /pubmed/33196798 http://dx.doi.org/10.1093/nar/gkaa1061 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Database Issue Gallo, Kathleen Goede, Andrean Eckert, Andreas Moahamed, Barbara Preissner, Robert Gohlke, Björn-Oliver PROMISCUOUS 2.0: a resource for drug-repositioning |
title | PROMISCUOUS 2.0: a resource for drug-repositioning |
title_full | PROMISCUOUS 2.0: a resource for drug-repositioning |
title_fullStr | PROMISCUOUS 2.0: a resource for drug-repositioning |
title_full_unstemmed | PROMISCUOUS 2.0: a resource for drug-repositioning |
title_short | PROMISCUOUS 2.0: a resource for drug-repositioning |
title_sort | promiscuous 2.0: a resource for drug-repositioning |
topic | Database Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779026/ https://www.ncbi.nlm.nih.gov/pubmed/33196798 http://dx.doi.org/10.1093/nar/gkaa1061 |
work_keys_str_mv | AT gallokathleen promiscuous20aresourcefordrugrepositioning AT goedeandrean promiscuous20aresourcefordrugrepositioning AT eckertandreas promiscuous20aresourcefordrugrepositioning AT moahamedbarbara promiscuous20aresourcefordrugrepositioning AT preissnerrobert promiscuous20aresourcefordrugrepositioning AT gohlkebjornoliver promiscuous20aresourcefordrugrepositioning |